TPCA-1

Cat. No.: HY-10074
CAS No.: 507475-17-4
Molecular Formula: C₁₂H₁₀FN₃O₂S
Molecular Weight: 279.29
Target: IKK
Pathway: NF-κB
Storage: Powder
-20°C 3 years
4°C 2 years
In solvent
-80°C 6 months
-20°C 1 month

Solvent & Solubility

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Mass (1 mg)</th>
<th>Mass (5 mg)</th>
<th>Mass (10 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>3.5805 mL</td>
<td>17.9025 mL</td>
<td>35.8051 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.7161 mL</td>
<td>3.5805 mL</td>
<td>7.1610 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.3581 mL</td>
<td>1.7903 mL</td>
<td>3.5805 mL</td>
</tr>
</tbody>
</table>

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (8.95 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (8.95 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (8.95 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC₅₀ of 17.9 nM.

IC₅₀ & Target
IKK-2
17.9 nM (IC₅₀)
## In Vitro
TPCA-1 significantly represses pro-inflammatory cytokines IL-8 and GRO-α in NPECs\(^1\). TPCA-1 inhibit NFκB activity as well as glioma cell proliferation and IL8 expression, and at concentrations of 2.5 and 5 μM, it blocks the TNF-induced p65 translocation into the nucleus of U87 cells\(^2\). TPCA-1 inhibits lipopolysaccharide-induced human monocyte production of TNF-α, IL-6, and IL-8 with an IC\(_{50}\)=170 to 320 nM\(^3\).

## In Vivo
TPCA-1 (3, 10, or 20 mg/kg, i.p.) results in a dose-dependent reduction in the severity of murine collagen-induced arthritis (CIA). TPCA-1 (10 mg/kg, i.p., b.i.d.) in vivo results in significantly decreased collagen-induced T cell proliferation ex vivo\(^3\).

## PROTOCOL

### Kinase Assay \(^3\)
Recombinant human IKK-2 (residues 1-756) is expressed in baculovirus as an N-terminal GST-tagged fusion protein, and its activity is assessed using a time-resolved fluorescence resonance energy transfer assay. In brief, IKK-2 (5 nM final) diluted in assay buffer (50 mM HEPES, 10 mM MgCl\(_2\), 1 mM CHAPS, pH 7.4, with 1 mM DTT and 0.01% w/v BSA) is added to wells containing various concentrations of compound or dimethyl sulfoxide (DMSO) vehicle (3% final). The reaction is initiated by the addition of GST-IkBα substrate (25 nM final)/ATP (1 μM final), in a total volume of 30 μL. The reaction is incubated for 30 min at room temperature, then terminated by the addition of 15 μL of 50 mM EDTA. Detection reagent (15 μL) in buffer (100 mM HEPES, pH 7.4, 150 mM NaCl, and 0.1% w/v BSA) containing antiphosphoserine-IkBα-32/36 monoclonal antibody 12C2, labeled with W-1024 europium chelate, and an allophycocyanin-labeled anti-GST antibody is added, and the reaction is further incubated for 60 min at room temperature. The degree of phosphorylation of GST-IkBα is measured as a ratio of specific 665-nm energy transfer signal to reference europium 620-nm signal, using a Packard Discovery plate reader.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Cell Assay \(^2\)
Ten μLs of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from stock solution (10 mg/mL) is added to each well of 96-well plates containing glioma cells and incubated at 37°C for 2-4 h. Oxidized MTT is solubilized by adding 100 μL of 10% sodium dodecyl sulfate (SDS) in 0.01 N HCl, and plates are incubated at 37°C for 4 h in a humidified chamber. Plates are read at 570 nm on a Bio-Rad plate reader.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration \(^3\)
Male DBA/1 OlaHsd mice are age of 6 to 8 weeks. On day 0, 10- to 12-week-old male DBA/1 mice are immunized intradermally at the base of the tail with a total of 100 μL of complete Freund’s adjuvant containing 200 μg of bovine type II collagen and 250 μg of Mycobacterium tuberculosis H37Ra. On day 21, mice are boosted intradermally with 100 μL of PBS containing 200 μg of bovine type II collagen. In all studies, TPCA-1 is administered in a vehicle consisting of 0.9% DMSO, 7% dimethylacetamide (DMA), and 10% Cremophor El. Etanercept (Enbrel) is administered in PBS. Where the effects of TPCA-1 and etanercept are compared, both treatment groups as well as their relevant vehicle-treated control groups are included in the same study. For prophylactic studies, TPCA-1 in vehicle or vehicle alone is administered i.p., b.i.d., beginning on day 1. Etanercept in PBS or PBS alone is administered i.p. every other day beginning on day 1. The incidence of disease exhibited by both vehicle-treated control groups (PBS- and DMSO/DMA/Cremophor-treated mice) is 100%. For therapeutic studies, administration of TPCA-1, etanercept, or their respective vehicles is initiated (day 1) once an animal exhibited a clinical score of “1” or greater for 2 consecutive days. Mice are scored daily for clinical symptoms of disease using a micrometer caliper to measure paw thickness.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA